Mimedx (MDXG) Other Non-Current Assets (2010 - 2026)
Mimedx (MDXG) posted Other Non-Current Assets of $11.9 million for Q2 2026, up 72.77% sequentially from $6.9 million in Q1 2026, and up 1101.72% YoY from $990000.0 in Q2 2025.
Mimedx (MDXG) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Mimedx has reported Other Non-Current Assets for 16 years, with the latest figure at $11.9 million in Q2 2026.
- Quarterly Other Non-Current Assets rose 1101.72% year-over-year to $11.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $11.9 million (up 1101.72% YoY) and the FY2025 annual result came in at $7.3 million, up 8.37% from the prior year.
- Other Non-Current Assets advanced to $11.9 million in Q2 2026 per MDXG's latest filing, from $6.9 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $11.9 million in Q2 2026 and troughed at $146000.0 in Q2 2023.
- A 5-year average of $2.5 million and a median of $1.1 million in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets tumbled 89.01% in 2023, then surged 3174.15% in 2024.
- Over 5 years, Other Non-Current Assets stood at $1.9 million in 2022, then sank by 89.01% to $205000.0 in 2023, then soared by 3174.15% to $6.7 million in 2024, then increased by 8.37% to $7.3 million in 2025, then surged by 63.56% to $11.9 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $11.9 million, $6.9 million, and $7.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | 11.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.90 Mn |
| Mar 31, 2026 | 6.89 Mn |
| Dec 31, 2025 | 7.27 Mn |
| Sep 30, 2025 | 2.99 Mn |
| Jun 30, 2025 | 990,000.00 |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 6.71 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | 205,000.00 |
| Sep 30, 2023 | 149,000.00 |
| Jun 30, 2023 | 146,000.00 |
| Mar 31, 2023 | 147,000.00 |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 150,000.00 |
| Jun 30, 2022 | 164,000.00 |
| Mar 31, 2022 | 172,000.00 |
| Dec 31, 2021 | 186,000.00 |
| Sep 30, 2021 | 270,000.00 |